GoodRx Holdings Inc (GDRX)

NASDAQHealth CareMedical - Healthcare Information ServicesSnapshot 2026-10-23

$3.54-2.21%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge GoodRx Holdings Inc’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

-1.4%

+10% or more+5%0%−5%−10% or less

0.36 → 0.35 EPS · FY ending Dec 31, 2027 · 8 analysts

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

Change in the same fiscal period’s mean EPS estimate from Sep 24, 2026 to Oct 24, 2026: (new ÷ prior − 1). Contributor count changed from 8 to 8; this is not the number of analysts revising. Source: FMP consensus snapshots. The ±10% axis is a display range.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	202.08M
EPS	—	0.08
Annual ending 2026-12-31
Revenue	—	799.58M
EPS	—	0.303
Annual ending 2027-12-31
Revenue	—	836.23M
EPS	—	0.351

Management figures unavailable.

What the Thesis Depends On

4 published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Defend market position against new entrants like TrumpRx	A primary condition in GoodRx Holdings Inc's published investment case. The stated target is No material loss of market share or pricing power in next 4 quarters.	Under Pressure	Significant market share loss or pricing pressure from competitors within next 4 quarters	Qualitative: Moat breach flagged vs No material loss target TrumpRx entry and generic drug additions flagged as legacy moat breach and zero-sum competitive threat to GoodRx. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Maintain stable management and governance	A supporting condition in GoodRx Holdings Inc's published investment case. The stated target is No further major executive or board departures in next 4 quarters.	Under Pressure	Additional key executive or board member departures within next 4 quarters	2 key departures vs 0 allowed Romin Nabiey (CAO) resigned in March 2026; Ian Clark (Director) resigned in April 2026. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Maintain strong profit margins and free cash flow yield near 11%	It has a strong profit margin and free cash flow yield of 11%.	Broken	FCF yield falls below 10% next 4 quarters	Free cash flow yield: 11.83% As of 2026-10-23; trailing twelve months. The target timing and basis require a separate assessment. Market data as of Oct 23, 202611.83 percent · calculatedLast status assessment Oct 24, 2026 Measurement source consolidated · TTM valuation Period ending Oct 23, 2026 Source: mart.stock_valuation_daily. Reference: GDRX:2026-10-23. Source status: canonical calculation. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 2 of last 2 quarters. Pharma Direct revenue grew 76% and subscription revenue grew 39% year-over-year in 2026-Q2, while total revenue slightly declined 1% to $200.4M. Adjusted EBITDA margin declined modestly from 34.2% to 31.8%. Management's focus on scaling these segments is delivering mixed results with strong segment growth but overall revenue slightly down and margin pressure. Delivery assessment Oct 24, 2026
Sustain revenue growth near $775 million in FY26	GoodRx helps people save on prescription drugs with steady revenue near $775 million in 2026.	Intact	revenue falls below $765 million in FY26	Revenue: $200.411M FY2026-Q2; GAAP. Published target: >= $765 million revenue in FY26. Target period is not explicitly aligned with this observation. Source published Aug 5, 2026200,411,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 6e4e4ea7-f874-4c57-bb46-36f6a51532dc. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 2 of last 2 quarters. Pharma Direct revenue grew 76% and subscription revenue grew 39% year-over-year in 2026-Q2, while total revenue slightly declined 1% to $200.4M. Adjusted EBITDA margin declined modestly from 34.2% to 31.8%. Management's focus on scaling these segments is delivering mixed results with strong segment growth but overall revenue slightly down and margin pressure. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$0.35

$0.36 → $0.35 · observed estimates

FY2027 revenue$0.84B

$0.82B → $0.84B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$0.36	$818,655,637	8 / 11
2026-07-25	$0.36	$817,915,110	12 / 14
2026-07-26	$0.36	$817,915,110	12 / 14
2026-07-27	$0.36	$817,910,658	8 / 11
2026-07-28	$0.36	$817,910,658	8 / 11
2026-07-29	$0.36	$817,910,658	8 / 11
2026-07-30	$0.36	$817,915,110	12 / 14
2026-07-31	$0.36	$817,915,110	12 / 14
2026-08-01	$0.36	$817,910,800	8 / 11
2026-08-02	$0.36	$817,910,800	8 / 11
2026-08-03	$0.36	$817,915,110	12 / 14
2026-08-04	$0.36	$817,915,110	12 / 14
2026-08-05	$0.36	$817,915,110	12 / 14
2026-08-06	$0.36	$817,910,800	8 / 11
2026-08-07	$0.36	$821,633,469	8 / 11
2026-08-08	$0.36	$828,347,620	12 / 14
2026-08-09	$0.36	$828,347,620	12 / 14
2026-08-10	$0.36	$821,633,469	8 / 11
2026-08-12	$0.36	$836,127,090	12 / 14
2026-08-13	$0.36	$821,633,469	8 / 11
2026-08-14	$0.36	$821,633,469	8 / 11
2026-08-15	$0.36	$821,633,469	8 / 11
2026-08-16	$0.36	$821,633,469	8 / 11
2026-08-17	$0.36	$821,633,469	8 / 11
2026-08-18	$0.36	$821,633,469	8 / 11
2026-08-19	$0.36	$821,633,469	8 / 11
2026-08-20	$0.36	$839,876,804	8 / 11
2026-08-21	$0.36	$839,876,804	8 / 11
2026-08-22	$0.36	$839,876,804	8 / 11
2026-08-23	$0.36	$839,876,804	8 / 11
2026-08-24	$0.36	$839,876,804	8 / 11
2026-08-25	$0.36	$839,876,804	8 / 11
2026-08-26	$0.36	$839,876,804	8 / 11
2026-08-27	$0.36	$839,876,804	8 / 11
2026-08-28	$0.36	$839,876,804	8 / 11
2026-08-29	$0.36	$839,876,804	8 / 11
2026-08-30	$0.36	$839,876,804	8 / 11
2026-08-31	$0.36	$839,876,804	8 / 11
2026-09-01	$0.36	$839,876,804	8 / 11
2026-09-02	$0.36	$839,876,804	8 / 11
2026-09-03	$0.36	$839,876,804	8 / 11
2026-09-04	$0.36	$839,876,804	8 / 11
2026-09-05	$0.36	$839,876,804	8 / 11
2026-09-06	$0.36	$839,876,804	8 / 11
2026-09-07	$0.36	$839,876,804	8 / 11
2026-09-08	$0.36	$839,876,804	8 / 11
2026-09-09	$0.36	$839,876,804	8 / 11
2026-09-10	$0.36	$839,876,804	8 / 11
2026-09-11	$0.36	$839,876,804	8 / 11
2026-09-12	$0.36	$839,876,804	8 / 11
2026-09-13	$0.36	$839,876,804	8 / 11
2026-09-14	$0.36	$839,876,804	8 / 11
2026-09-15	$0.36	$839,876,804	8 / 11
2026-09-16	$0.36	$839,876,804	8 / 11
2026-09-17	$0.36	$839,876,804	8 / 11
2026-09-18	$0.36	$839,876,804	8 / 11
2026-09-19	$0.36	$839,876,804	8 / 11
2026-09-20	$0.36	$839,876,804	8 / 11
2026-09-21	$0.36	$839,876,804	8 / 11
2026-09-22	$0.36	$839,876,804	8 / 11
2026-09-23	$0.36	$839,876,804	8 / 11
2026-09-24	$0.36	$839,876,804	8 / 11
2026-09-25	$0.36	$839,876,804	8 / 11
2026-09-26	$0.36	$839,876,804	8 / 11
2026-09-27	$0.36	$839,876,804	8 / 10
2026-09-28	$0.36	$839,876,804	8 / 10
2026-09-29	$0.35	$838,387,341	8 / 10
2026-09-30	$0.35	$838,387,341	8 / 10
2026-10-01	$0.35	$838,387,341	8 / 10
2026-10-02	$0.35	$838,387,341	8 / 10
2026-10-03	$0.35	$838,387,341	8 / 10
2026-10-04	$0.35	$838,387,341	8 / 10
2026-10-05	$0.35	$838,387,341	8 / 10
2026-10-06	$0.35	$838,387,341	8 / 10
2026-10-07	$0.35	$838,387,341	8 / 10
2026-10-08	$0.35	$838,388,687	8 / 10
2026-10-09	$0.35	$838,388,687	8 / 10
2026-10-10	$0.35	$838,388,687	8 / 10
2026-10-11	$0.35	$838,388,687	8 / 10
2026-10-12	$0.35	$838,388,687	8 / 10
2026-10-13	$0.35	$838,388,687	8 / 10
2026-10-14	$0.35	$835,933,380	8 / 10
2026-10-15	$0.35	$835,933,380	8 / 10
2026-10-16	$0.35	$835,933,380	8 / 10
2026-10-17	$0.35	$835,933,380	8 / 10
2026-10-18	$0.35	$835,933,534	8 / 10
2026-10-19	$0.35	$835,933,534	8 / 10
2026-10-20	$0.35	$836,223,603	8 / 10
2026-10-21	$0.35	$836,225,841	8 / 10
2026-10-22	$0.35	$836,225,841	8 / 10
2026-10-23	$0.35	$836,225,841	8 / 10
2026-10-24	$0.35	$836,225,841	8 / 10

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	5	8	2
2026-06-01	5	8	2
2026-07-01	5	8	2
2026-08-01	5	8	2
2026-09-01	5	8	2
2026-10-01	4	8	2

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 4 Buy / Strong Buy · 8 Hold · 2 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Defend market position against new entrants like TrumpRxPublished status: Under Pressure
Maintain stable management and governancePublished status: Under Pressure
Maintain strong profit margins and free cash flow yield near 11%Published status: Broken
Sustain revenue growth near $775 million in FY26Revenue: $200.411M

Next proof point

Nov 3, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.9%Typical daily move · historical

Downside history

-52.7%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

GoodRx Holdings Inc outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a growth and profitability story with strong recent financial performance, robust earnings quality, and a supportive Healthcare sector backdrop. The long-term thesis is intact, but the business still carries high risk and management execution is mixed.

What's priced into GoodRx Holdings Inc

The evidence says GDRX is cheap versus peers, while its priced-in tag is justified and the expectations gap is slightly negative. Valuation confidence is low, so the gap between expectations and results is not clear-cut.

What the fundamentals likely do

Near term, Pharma Direct and subscription growth are strong, and management raised its 2026 Adjusted EBITDA guidance; quarterly Adjusted EBITDA also increased. However, total revenue edged down and the Adjusted EBITDA margin narrowed in 2026-Q2, while recent earnings reports were in line and the evidence notes a history of recent misses.

What GoodRx Holdings Inc hinges on

The multi-year view hinges on whether growth in Pharma Direct and subscriptions can support overall revenue while margins remain strong. Near term, a guidance cut after the recent raise would damage management credibility, while further weakening in jobs data could add pressure; continued strength from Healthcare peers would support the sector backdrop.